Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ASTX-660 |
Synonyms | |
Therapy Description |
ASTX-660 is a SMAC mimetic that inhibits cIAP and XIAP, potentially resulting in tumor cell death (Cancer Res 2016;76(14 Suppl):Abstract nr 1287, PMID: 31900279). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ASTX-660 | ASTX660|ASTX 660 | SMAC Mimetic 8 | ASTX-660 is a SMAC mimetic that inhibits cIAP and XIAP, potentially resulting in tumor cell death (Cancer Res 2016;76(14 Suppl):Abstract nr 1287, PMID: 31900279). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04155580 | Phase I | ASTX-660 ASTX-660 + Decitabine and Cedazuridine | A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) | Terminated | USA | 0 |
NCT02503423 | Phase Ib/II | ASTX-660 | Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas | Active, not recruiting | USA | ITA | HUN | GBR | FRA | ESP | CAN | BEL | 0 |